Patrick Baeuerle - 10 Aug 2021 Form 4 Insider Report for Cullinan Oncology, Inc. (CGEM)

Role
Acting Chief Scientific Officer, Biologics
Signature
/s/ Jeffrey Trigilio, Attorney-in-Fact
Issuer symbol
CGEM
Transactions as of
10 Aug 2021
Net transactions value
-$249,700
Form type
4
Filing time
26 Aug 2021, 19:11:47 UTC
Next filing
09 Sep 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CGEM Common Stock Options Exercise $47,300 +11,000 $4.30 11,000 10 Aug 2021 Direct
transaction CGEM Common Stock Sale $297,000 -11,000 -100% $27.00 0 10 Aug 2021 Direct F1
holding CGEM Common Stock 341,434 10 Aug 2021 See Footnote F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CGEM Stock Option (Right to Buy) Options Exercise $0 -11,000 -4.2% $0.000000 251,114 10 Aug 2021 Common Stock 11,000 $4.30 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 30, 2021.
F2 Shares held directly by APAK Solutions GmbH. The Reporting Person is managing director of APAK Solutions GmbH. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
F3 25% of the shares vested on September 1, 2019, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

Remarks:

Acting Chief Scientific Officer, Biologics